← Back to Search

Neuromodulation

Neuromodulation for Depression

N/A
Waitlist Available
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Normal or corrected-to normal vision and hearing
For group with depression, current diagnosis of depression
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 hours
Awards & highlights

Study Summary

This trial is testing if a new treatment, LIFUP, can change negative cognition in depression by modulating the activity of the brain's Default Mode Network. The study will investigate if this treatment can decrease mind-wandering and increase mindfulness.

Who is the study for?
This trial is for right-handed adults aged 18-64 with a current diagnosis of depression. Participants must have normal or corrected-to-normal vision and hearing, without significant medical illnesses, neurological disorders, or MRI scan contraindications like metal implants.Check my eligibility
What is being tested?
The study tests the BrainSonix Pulsar 1002's ability to modulate brain activity in the posterior cingulate cortex (PCC) to potentially reduce negative mind-wandering associated with depression. It will explore if altering PCC activity can affect mindfulness and cognitive-affective tasks.See study design
What are the potential side effects?
Potential side effects are not explicitly listed but may include discomfort from wearing the device, headache, dizziness, or other sensations related to non-invasive brain stimulation.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My vision and hearing are normal, or corrected to be normal.
Select...
I am currently diagnosed with depression.
Select...
I am between 18 and 64 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Default mode network activation during task
Negative self-judgment frequency during task
Rumination
Secondary outcome measures
Default mode network connectivity
Depressive Symptoms

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Active LIFUPActive Control1 Intervention
All participants will receive active modulation of the posterior cingulate cortex (PCC) during Visit 3 or 4 (order counterbalanced).
Group II: Sham LIFUPPlacebo Group1 Intervention
All participants will receive sham modulation of the posterior cingulate cortex (PCC) during Visit 3 or 4 (order counterbalanced).

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,928 Previous Clinical Trials
13,198,275 Total Patients Enrolled
184 Trials studying Depression
29,476 Patients Enrolled for Depression

Media Library

BrainSonix Pulsar 1002 (Neuromodulation) Clinical Trial Eligibility Overview. Trial Name: NCT04832685 — N/A
Depression Research Study Groups: Active LIFUP, Sham LIFUP
Depression Clinical Trial 2023: BrainSonix Pulsar 1002 Highlights & Side Effects. Trial Name: NCT04832685 — N/A
BrainSonix Pulsar 1002 (Neuromodulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04832685 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the trial cohort include individuals aged sixty or above?

"This trial is looking for 18 to 64 year olds, but there are 192 trials targeting minors and 962 clinical studies focusing on elderly patients."

Answered by AI

Are there any prerequisites for individuals to qualify as a participant in this trial?

"This study is enlisting 20 individuals aged between 18 and 64 who are diagnosed with depression. Eligible participants must be right-handed, have normal or corrected-to-normal vision and hearing, and meet other criteria necessary to qualify for this trial."

Answered by AI

Is this trial actively recruiting participants?

"The research posted on clinicaltrials.gov reveals that this study is not actively seeking out potential participants at the moment. Initially put up for public viewing on February 1st 2023, and last modified April 4th 2022, it does not currently have a vacancy for individuals to take part in the trial. Nevertheless, there are still 1288 other medical studies recruiting patients right now."

Answered by AI

Who else is applying?

What state do they live in?
Massachusetts
How old are they?
18 - 65
What site did they apply to?
Massachusetts General Hospital
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Neuromodulation of Mind-Wandering in Depression
Darin Dougherty, MD 2023. "Neuromodulation of Mind-Wandering in Depression". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04832685.
All > Depression Boston
~37 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top